In the first quarter of 2016, the Group’s net profit, attributable to shareholders of the parent company, was 0.05 million euro and has decreased by 1.4 million euro or 96.5 % compared to the first three months of 2015. Gross profit margin in the first quarter of 2016 was 44.6%, while net profit margin was 0.2%. In the first three months of 2016, the Group’s production was exported to 53 countries worldwide, a total of 18.8 million euro which is by 1.8 million euro or 8.6% less than in the first quarter of 2015.

Sales volume of the final dosage forms of Grindeks in the first quarter of 2016 was 19.2 million euro and has decreased by 0.04 million euro or 0.2% in comparison to the first three months of 2015. In the first quarter of 2016, the sales amount in Russia, other CIS countries and Georgia reached 10.0 million euro, which is by 2.2 million euro or 18.3% less than in the first quarter of 2015. In comparison to the first three months of 2015, the biggest increase in sales volume has been reached in Ukraine (8%), Georgia (4%) and Moldova (3%).

Due to the business diversification strategy and the development of company’s activities in the new markets, sales volume in the Baltic States and other countries reached 9.2 million euro which is by 2.2 million euro or 31.8% more than in the first quarter of 2015. The sales volume in Canada compared with the first three months of 2015, has increased by 3.6 times, in Poland – 2.5 times, while in Hungary it has increased by 88%. In the first quarter of 2016, the sales volume in Latvia reached 1.7 million euro and has increased by 0.2 million euro or 11.5% in comparison with the first three months of 2015.

In the first quarter of 2016, sales of the active pharmaceutical ingredients reached 1.5 million euro, which is by 1.6 million euro or 52.1% less than in 2015. The key markets of «Grindeks» active pharmaceutical ingredients are the EU countries, U.S., Australia and Japan. The most required active pharmaceutical ingredients of Grindeks in the first three months of 2016 were oxytocin, droperidol, pimobendan, detomidine and xylazine.

Juris Bundulis, the Chairman of the Board of JSC Grindeks: „By using our knowledge and experience, company’s orientation to new markets is progressing well. However, considering the specificities of pharmaceutical business, reorientation from one region to another requires patience, time and recourses. In comparison with the previous years, this year the amount of registered drugs in the new markets will significantly grow, leading to increase in sales in both the near and distant future. Pleasantly, in the first quarter our operations in Russia and Ukraine, quite essential markets for Grindeks, have marked a positive trend, stabilizing the overall situation and motivating us to continue what has been started.”

 

Grindeks unaudited financial statements on the three months of 2016 (395 KB)